Botulinum Toxin E-Book , livre ebook
814
pages
English
Ebooks
2009
Vous pourrez modifier la taille du texte de cet ouvrage
Obtenez un accès à la bibliothèque pour le consulter en ligne En savoir plus
Découvre YouScribe en t'inscrivant gratuitement
Découvre YouScribe en t'inscrivant gratuitement
814
pages
English
Ebook
2009
Vous pourrez modifier la taille du texte de cet ouvrage
Obtenez un accès à la bibliothèque pour le consulter en ligne En savoir plus
Publié par
Date de parution
18 février 2009
Nombre de lectures
1
EAN13
9781437711196
Langue
English
Poids de l'ouvrage
6 Mo
- Provides clinical applications of botulinum toxin for over 100 disorders for immediate access and easy reference during practice and treatment.
- Covers a broad array of hot topics, including botulinum toxin applications for the treatment of cranial-cervical dystonias, motor disorders in cerebral palsy, bruxism and temporomandibular disorders, headache, overactive bladder, chronic pelvic pain syndromes, arthritis joint pain, and wound healing.
- Focuses on approved uses with expert advice on thoroughly tested applications but also discusses new and emerging applications to expose you to additional treatment options.
- Presents the most comprehensive and up-to-date material available so you get all the information you need from this one resource.
- Offers the cross-disciplinary guidance of the best world-class expertise through an authoritative, international group of authors who demonstrate the applications of botulinum toxin across various specialties.
Publié par
Date de parution
18 février 2009
Nombre de lectures
1
EAN13
9781437711196
Langue
English
Poids de l'ouvrage
6 Mo
Botulinum Toxin
Therapeutic Clinical Practice and Science
First Edition
Joseph Jankovic, MD
Chief Editor , Professor of Neurology, Distinguished Chair in Movement Disorders, Director of Parkinson’s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas
Alberto Albanese, MD
Professor of Neurology, Center for Neurosciences, Catholic University, Head Neurologist, National Neurological Institute Carlo Besta, Milan, Italy
M. Zouhair Atassi, PhD, DSc
Robert A. Welch Chair of Chemistry, Professor of Biochemistry and Molecular Biology, Professor of Immunology, Baylor College of Medicine, Houston, Texas
J. Oliver Dolly, MSc, PhD, DSc
Science Foundation Ireland Research Professor, Director, International Centre for Neurotherapeutics, Dublin City University, Dublin, Ireland
Mark Hallett, MD
Chief, Human Motor Control Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland
Nathaniel H. Mayer, MD
Emeritus Professor of Physical Medicine and Rehabilitation, Temple University School of Medicine, Philadelphia, Pennsylvania, Director, Motor Control Analysis Laboratory, MossRehab, Elkins Park, Pennsylvania
Copyright © 2009 by Saunders, an imprint of Elsevier Inc.
Saunders Elsevier
Copyright
SAUNDERS
ELSEVIER
1600 John F. Kennedy Blvd.
Ste 1800
Philadelphia, PA 19103-2899
BOTULINUM TOXIN: ISBN: 978-1-4160-4928-9
THERAPEUTIC CLINICAL PRACTICE AND SCIENCE
Copyright © 2009 by Saunders, an imprint of Elsevier Inc.
All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Permissions may be sought directly from Elsevier’s Rights Department: phone: (+1) 215 239 3804 (US) or (+44) 1865 843830 (UK); fax: (+44) 1865 853333; e-mail: healthpermissions@elsevier.com . You may also complete your request on-line via the Elsevier website at http://www.elsevier.com/permissions .
Notice
Knowledge and best practice in this field are constantly changing. As new research and experience broaden our knowledge, changes in practice, treatment, and drug therapy may become necessary or appropriate. Readers are advised to check the most current information provided (i) on procedures featured or (ii) by the manufacturer of each product to be administered to verify the recommended dose or formula, the method and duration of administration, and contraindications. It is the responsibility of the practitioner, relying on his or her own experience and knowledge of the patient, to make diagnoses, to determine dosages and the best treatment for each individual patient, and to take all appropriate safety precautions. To the fullest extent of the law, neither the Publisher nor the Authors assumes any liability for any injury and/or damage to persons or property arising out of or related to any use of the material contained in this book.
The Publisher
Library of Congress Cataloging-in-Publication Data
Botulinum toxin : therapeutic clinical practice and science / [edited by] Joseph Jankovic… [et al.]. – 1st ed.
p. ; cm.
Includes bibliographical references.
ISBN 978-1-4160-4928-9
1. Botulinum toxin–Therapeutic use. I. Jankovic, Joseph.
[DNLM: 1. Botulinum Toxins–therapeutic use. QV 140 B751 2008]
RC935.S64B68 2008
615′.329364–dc22 2008043233
Acquisitions Editor: Adrianne Brigido
Developmental Editor: Angela Norton
Project Manager: David Saltzberg
Design Direction: Steven Stave
Printed in United States of America
Last digit is the print number: 9 8 7 6 5 4 3 2 1
Contributors
Giovanni Abbruzzese, MD, PhD, Professor of Neurology, Department of Neurosciences, Ophthalmology and Genetics, University of Genoa, Genoa, Italy, Effects of Botulinum Toxin on Central Nervous System Function
Emily J. Adams, BSc (Hons), PhD, Postdoctoral Research Fellow, National Heart and Lung Institute, Imperial College London, London, United Kingdom, Understanding Botulinum Neurotoxin Mechanism of Action and Structure to Enhance Therapeutics and Improve Care
Alberto Albanese, MD, Professor of Neurology, Center for Neurosciences, Catholic University; Head Neurologist, National Neurological Institute Carlo Besta, Milan, Italy, Botulinum Neurotoxin in Tremors, Tics, Hemifacial Spasm, Spasmodic Dysphonia, and Stuttering; Clinical Trials of Botulinum Toxin in Adult Spasticity
K. Roger Aoki, PhD, Vice President, Neurotoxins, Discovery Research, Allergan, Inc., Irvine, California, Immune Recognition of Botulinum Neurotoxins A and B: Molecular Elucidation of Immune Protection Against the Toxins
Debra Elaine Artim, PhD, Research Associate, Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, Bungarotoxins
M. Zouhair Atassi, PhD, DSc, Robert A. Welch Chair of Chemistry, Professor of Biochemistry and Molecular Biology, and Professor of Immunology, Baylor College of Medicine, Houston, Texas, Immune Recognition of Botulinum Neurotoxins A and B: Molecular Elucidation of Immune Protection Against the Toxins
Anna Rita Bentivoglio, MD, PhD, Confirmed Researcher, Istituto di Neurologia, Università Cattolica del Sacro Cuore; Assistant Professor of Neurology, Istituto di Neurologia, Policlinico Agostino Gemelli, Rome, Italy, Botulinum Neurotoxin in Tremors, Tics, Hemifacial Spasm, Spasmodic Dysphonia, and Stuttering
Alfredo Berardelli, MD, PhD, Professor of Neurology, Department of Neurological Sciences and Neuromed Institute, “Sapienza” University of Rome, Rome, Italy, Effects of Botulinum Toxin on Central Nervous System Function
Hans Bigalke, MD, Institute of Toxicology, Hannover Medical School, Hannover, Germany, Properties of Pharmaceutical Products of Botulinum Neurotoxins
Andrew Blitzer, MD, DDS, Professor of Clinical Otolaryngology, College of Physicians and Surgeons, Columbia University; Senior Attending Otolaryngologist, St. Luke’s/Roosevelt Hospital Center; Director, New York Center for Voice and Swallowing Disorders, New York, New York, Treatment of Oromandibular Dystonia, Bruxism, and Temporomandibular Disorders with Botulinum Toxin
MacDara Bodeker, PhD, International Centre for Neurotherapeutics, Dublin City University, Dublin, Ireland, Multiple Steps in the Blockade of Exocytosis by Botulinum Neurotoxins
Mark A. Breidenbach, PhD, Postdoctoral Fellow, Department of Chemistry, University of California, Berkeley, Berkeley, California, Interactions Between Botulinum Neurotoxins and Synaptic Vesicle Proteins
Axel T. Brunger, PhD, Professor, Stanford University School of Medicine, Stanford, California, Interactions Between Botulinum Neurotoxins and Synaptic Vesicle Proteins
Michael B. Chancellor, MD, Director of Neurourology Program, Department of Urology, William Beaumont Hospital, Royal Oak, Michigan, Mechanism of Action of Botulinum Neurotoxin in the Lower Urinary Tract; Application of Botulinum Toxin in the Prostate
Martin K. Childers, DO, PhD, Associate Professor, Department of Neurology, Wake Forest University Health Sciences, Winston-Salem, North Carolina, Clinical Application of Botulinum Neurotoxin in the Treatment of Myofascial Pain Syndromes
Yao-Chi Chuang, MD, Associate Professor, Department of Urology, Chang Gung University, Kaohsiung Hsien, Taiwan, Application of Botulinum Toxin in the Prostate
Cynthia L. Comella, MD, Professor, Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, Comparative Clinical Trials of Botulinum Toxins
William Chet de Groat, PhD, Professor of Pharmacology, Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, Bungarotoxins
J. Oliver Dolly, MSc, PhD, DSc, Science Foundation Ireland Research Professor, and Director, International Centre for Neurotherapeutics, Dublin City University, Dublin, Ireland, Multiple Steps in the Blockade of Exocytosis by Botulinum Neurotoxins
Wagner Ferreira dos Santos, BsC, MsC, PhD, Associate Professor, Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil, Spider and Wasp Neurotoxins
Dirk Dressler, MD, PhD, Professor of Neurology, and Head, Movement Disorders Section, Department of Neurology, Hannover Medical School, Hannover, Germany, Comparative Clinical Trials of Botulinum Toxins
Dennis Dykstra, MD, PhD, MHA, Associate Professor, and Chairman, Department of Physical Medicine and Rehabilitation, University of Minnesota Medical School, Minneapolis, Minnesota, Botulinum Toxin in Overactive Bladder; Botulinum Toxin for Osteoarticular Pain
Roberto Eleopra, MD, Chairman of Neurological Department, Angel’s Hospital of Mestre, Venice, Italy, Biology and Clinical Pharmacology of Botulinum Neurotoxin Type C and Other Non-A/Non-B Botulinum Neurotoxins
Antonio Elia, MD, Department of Neurology, National Neurological Institute Carlo Besta, Milan, Italy, Clinical Trials of Botulinum Toxin in Adult Spasticity
Alberto Esquenazi, MD, Professor of Physical Medicine and Rehabilitation, Jefferson School of Medicine, Thomas Jefferson University, Philadelphia; Chair of Physical Medicine and Rehabilitation, and Director, Gait and Motion Analysis Laboratory, MossRehab, E
